TrialCancer chemotherapy and pharmacology2013

An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo.

Pradip De et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.